Century Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 9, 2024. Century is a clinical-stage biotechnology company developing iPSC-derived cell therapies for cancer and autoimmune diseases. It has no approved products and has not generated product sales revenue.
Key financial metrics
Amounts in millions, except per-share data. The filing presents unaudited results.
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Collaboration revenue | $0.9 | $1.7 |
| Research and development expense | $23.4 | $24.9 |
| General and administrative expense | $8.7 | $8.9 |
| Total operating expenses | $32.2 | $33.8 |
| Loss from operations | $(31.3) | $(32.1) |
| Interest income | $3.2 | $2.6 |
| Net loss | $(28.1) | $(31.3) |
| Net loss per share, basic and diluted | $(0.45) | $(0.53) |
| Net cash used in operating activities | $(30.2) | $(29.2) |
- Liquidity: At March 31, cash and cash equivalents were $46.8 million and investments were $203.1 million, totaling $249.9 million. Current assets were $199.8 million and current liabilities $16.1 million.
- Cash flows: Investing activities provided $11.5 million, mainly from net sales of available-for-sale securities; financing activities provided $18.2 million, including $17.8 million net ATM proceeds. Cash, cash equivalents and restricted cash ended the quarter at $48.8 million.
- Debt and leases: The Hercules term loan was repaid in May 2023; no interest expense was recorded in Q1 2024. Operating lease liabilities totaled $46.5 million, with $81.9 million of undiscounted future lease payments.
- Margins: Product-sales margins are not applicable; the company has no product sales. Collaboration revenue is recognized as services are performed and varies with the timing and level of related costs.
Material changes versus prior-year quarter
- Revenue fell $0.9 million, while total operating expenses declined $1.6 million; operating loss narrowed $0.8 million and net loss improved $3.2 million.
- R&D expense decreased $1.5 million. Lower personnel and facility costs following the 2023 workforce reduction and site consolidation were partly offset by higher research and laboratory costs, including increased manufacturing activity at the Branchburg facility.
- Operating cash use increased $1.0 million. ATM sales generated $17.8 million net financing proceeds, versus no ATM proceeds in Q1 2023.
- Shares issued and outstanding rose from 60.3 million at December 31, 2023 to 64.8 million at March 31, 2024, primarily reflecting ATM issuance.
Outlook, developments and risks
- Management said cash, cash equivalents and investments were expected to fund operating expenses and capital expenditures into 2026, based on current plans and assumptions. The company expects further losses and anticipates it will need additional financing; it cautions that actual cash needs could exceed estimates.
- In April 2024, after quarter-end, Century closed a private placement of 15,873,011 shares at $3.78 per share, receiving approximately $56.7 million net. It intends to support CNTY-101 development in autoimmune indications and general corporate needs.
- Also in April, Century acquired Clade Therapeutics for approximately $15 million cash and 4,535,333 Century shares, with a potential $10 million clinical-development milestone. Acquisition accounting was still under evaluation at the filing date. The acquisition adds three preclinical programs and iPSC-derived T-cell capabilities; integration and realization of expected benefits are risks.
- Pipeline focus includes CNTY-101, including a planned SLE trial initiation in the first half of 2024 and initial data expected by year-end 2024; CNTY-102 and CNTY-107; and partnered programs with Bristol Myers Squibb. Management described plans announced in Q2 2024 to expand CNTY-101 into additional autoimmune indications, with further regulatory filings expected in the second half of 2024.
- The Bristol Myers Squibb collaboration generated $0.9 million of Q1 revenue. Deferred collaboration revenue was $114.9 million at March 31, including $109.2 million allocated to unexercised license options. Potential development and regulatory milestones remain contingent.
- Key risks include clinical and regulatory uncertainty, dependence on CNTY-101 and collaborators, manufacturing and supplier reliance (including FCDI), need for future capital and potential dilution, competition, and Clade integration. The filing reported no pending legal matters believed likely to have a material adverse effect and no material change in internal controls.
Important facts for investors to verify
- Whether clinical milestones for CNTY-101, including the SLE trial and planned data timing, are achieved and what the emerging data show.
- Whether the stated runway into 2026 remains supportable after expanded development plans, the Clade acquisition and actual cash burn.
- The full share-count and dilution impact of the April private placement, Clade consideration, and any further ATM sales.
- Clade’s final accounting treatment, integration costs, and progress toward the expected strategic benefits.
- The timing and terms of any Bristol Myers Squibb option exercises or milestone payments, and the pace at which deferred collaboration revenue is recognized.